Accuray Toekomstige groei

Future criteriumcontroles 3/6

De verwachting is dat Accuray de winst en omzet met respectievelijk 81.4% en 4.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 83.8% per jaar.

Belangrijke informatie

81.4%

Groei van de winst

83.77%

Groei van de winst per aandeel

Medical Equipment winstgroei	15.9%
Inkomstengroei	4.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Apr 2026

Recente toekomstige groei-updates

Recent updates

Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access

Feb 21Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?

The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%

Feb 06

Groundhog Day Once Again, As Accuray Misses And Lowers

Feb 06

Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business

Feb 06Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?

Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital

Dec 20

Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding

Dec 02

Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues

Jun 28

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Apr 04

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop

Mar 11

Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth

Jan 18

Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'

Jan 07

Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?

Dec 19

Accuray Incorporated: Cheap, But With Caveats

Dec 05

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Aug 18

Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues

Aug 13

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

May 21

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

May 04

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

May 03

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Apr 07

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Feb 03

Winst- en omzetgroeiprognoses

NasdaqGS:ARAY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2028	483	15	N/A	N/A	1
6/30/2027	464	-13	N/A	N/A	2
6/30/2026	443	-34	N/A	N/A	2
12/31/2025	437	-36	-11	5	N/A
9/30/2025	451	-19	11	22	N/A
6/30/2025	459	-2	-6	3	N/A
3/31/2025	465	1	17	22	N/A
12/31/2024	453	-4	-8	-4	N/A
9/30/2024	444	-17	-14	-11	N/A
6/30/2024	447	-16	-16	-12	N/A
3/31/2024	431	-21	-24	-13	N/A
12/31/2023	447	-15	8	20	N/A
9/30/2023	455	-7	-6	7	N/A
6/30/2023	448	-9	3	16	N/A
3/31/2023	439	-10	-4	2	N/A
12/31/2022	417	-12	-50	-44	N/A
9/30/2022	419	-10	2	6	N/A
6/30/2022	430	-5	-7	-2	N/A
3/31/2022	431	-13	4	8	N/A
12/31/2021	437	-12	43	46	N/A
9/30/2021	418	-8	30	33	N/A
6/30/2021	396	-6	36	39	N/A
3/31/2021	380	5	49	51	N/A
12/31/2020	377	8	21	23	N/A
9/30/2020	379	14	17	20	N/A
6/30/2020	383	4	-5	-1	N/A
3/31/2020	405	3	-15	-11	N/A
12/31/2019	409	-1	-11	-6	N/A
9/30/2019	413	-17	N/A	-36	N/A
6/30/2019	419	-16	N/A	-30	N/A
3/31/2019	415	-16	N/A	-11	N/A
12/31/2018	412	-24	N/A	0	N/A
9/30/2018	410	-24	N/A	14	N/A
6/30/2018	405	-24	N/A	18	N/A
3/31/2018	403	-28	N/A	14	N/A
12/31/2017	401	-24	N/A	-3	N/A
9/30/2017	388	-29	N/A	-7	N/A
6/30/2017	383	-30	N/A	0	N/A
3/31/2017	366	-32	N/A	-4	N/A
12/31/2016	374	-26	N/A	0	N/A
9/30/2016	396	-22	N/A	12	N/A
6/30/2016	399	-26	N/A	31	N/A
3/31/2016	406	-24	N/A	7	N/A
12/31/2015	398	-28	N/A	17	N/A
9/30/2015	387	-32	N/A	10	N/A
6/30/2015	380	-40	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ARAY de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.4% ).

Winst versus markt: Er wordt verwacht dat ARAY de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ARAY binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ARAY ( 4.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.2% per jaar).

Hoge groei-inkomsten: De omzet van ARAY ( 4.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ARAY naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/04 18:38
Aandelenkoers aan het einde van de dag	2026/05/04 00:00
Inkomsten	2025/12/31
Jaarlijkse inkomsten	2025/06/30

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Accuray Incorporated wordt gevolgd door 16 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Neil Chatterji	B. Riley Securities, Inc.
Marie Thibault	BTIG
Michael Gorman	BTIG

Accuray Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Accuray Incorporated Updates Earnings Guidance for the Fiscal Year 2026

Consensus EPS estimates fall by 929%

Forecast breakeven date pushed back to 2028

Accuray Incorporated Reaffirms Earnings Guidance for the Fiscal Year 2026

Price target decreased by 8.1% to US$4.75

Consensus estimates of losses per share improve by 36%

Recent updates

Accuray Incorporated to Report Q3, 2026 Results on May 06, 2026

Accuray Incorporated Appoints Paul Miele As Senior Vice President And Chief Commercial Officer, Effective April 6, 2026

Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access

Accuray Incorporated announced delayed 10-Q filing

Accuray Incorporated Receives Notice of Non-Compliance with Nasdaq Bid Price Rule

The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%

Groundhog Day Once Again, As Accuray Misses And Lowers

Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Updates Earnings Guidance for the Fiscal Year 2026

Accuray Incorporated to Report Q2, 2026 Results on Feb 04, 2026

Accuray Incorporated Announces Resignation of Sandeep Chalke as Senior Vice President and Chief Commercial Officer, Effective March 31, 2026

Accuray Incorporated Announces Retirement of Byron C. Scott as Class III Director and Including All Committees, Effective December 31, 2025

New minor risk - Market cap size

Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital

Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Consensus EPS estimates fall by 929%

Forecast breakeven date pushed back to 2028

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Accuray Incorporated Reaffirms Earnings Guidance for the Fiscal Year 2026

Accuray Incorporated to Report Q1, 2026 Results on Nov 05, 2025

Accuray Incorporated Announces Executive Changes

Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price

Accuray Incorporated Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System

Accuray Incorporated, Annual General Meeting, Nov 13, 2025

Accuray Incorporated Launches All-In-One Radiotherapy Solution with Advanced Capabilities Designed to Set A New Standard in Cancer Care

Price target decreased by 8.1% to US$4.75

Accuray Incorporated Announces Management Resignation

Consensus estimates of losses per share improve by 36%

Full year 2025 earnings: EPS misses analyst expectations

Accuray Incorporated Provides Earnings Guidance for Fiscal Year Ending June 30, 2026

Returns At Accuray (NASDAQ:ARAY) Are On The Way Up

Accuray Incorporated to Report Q4, 2025 Results on Aug 13, 2025

Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues

Independent Chairman of the Board recently bought US$62k worth of stock

Price target decreased by 8.1% to US$5.17

Accuray Incorporated Appoints Steven F. Mayer to Its Board

Price target decreased by 8.2% to US$5.63

Accuray Incorporated Provides Earnings Guidance for the Fourth Quarter of 2025

New major risk - Financial position

Accuray Incorporated Provides Earnings Guidance for the Full Year 2025

Insufficient new directors

Accuray Incorporated to Report Q3, 2025 Results on Apr 30, 2025

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Accuray Incorporated Announces New Data on the Clinical Use of the CyberKnife System

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Raises Earnings Guidance for the Year 2025

Accuray Incorporated to Report Q2, 2025 Results on Feb 05, 2025

Accuray Incorporated Appoints Leonel Peralta as Senior Vice President, Chief Operations Officer, Effective February 3, 2025

Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth

Accuray Incorporated Announces China National Medical Products Administration Approval of Radixact SynC and CyberKnife S7 Systems

Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'

Health Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?

Accuray Incorporated Announces the Departure of Michael Hoge as Senior Vice President, Global Operations, Effective January 6, 2025

Accuray Incorporated: Cheap, But With Caveats

Accuray Incorporated Approves to Appoint Michael Murphy as the Principal Accounting Officer, Effective December 2, 2024

Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025

Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024

Accuray Incorporated Announces CEO Changes

Accuray Incorporated, Annual General Meeting, Nov 21, 2024

Accuray Incorporated announced delayed annual 10-K filing

Accuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of Absence

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025